FDA Accepts BeiGene’s BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma

Goodwin
Contact

Goodwin

On September 13, 2021 BeiGene announced the FDA’s acceptance of its BLA for tislelizumab in esophageal squamous cell carcinoma (ESCC).  While tislelizumab is already approved for five indications in China, this marks the first ex-China regulatory filing for the biologic.  The BLA was filed in collaboration with Novartis and is supported by the Phase 3 RATIONALE 302 trial.  As Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene stated, “Our uniquely designed anti-PD-1 antibody tislelizumab has been shown to significantly improve survival compared to chemotherapy for people with a variety of solid tumors and hematologic malignancies. We previously shared the compelling results at ASCO 2021 with tislelizumab significantly prolonging survival and demonstrating a favorable safety profile over chemotherapy in patients with locally advanced or metastatic ESCC, a devastating disease with an average five-year survival rate of just five percent.  This BLA acceptance brings us closer to potentially providing tislelizumab as a treatment for these patients in the United States.”  Tislelizumab is also currently under regulatory review in China as a treatment for patients with locally advanced or metastatic ESCC who have disease progression following, or are intolerant to, first-line standard chemotherapy.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.